Theralase Technologies Inc - TLTFF STOCK NEWS

Theralase Technologies has announced promising preclinical results for its lead drug, Rutherrin, which increases the efficacy of chemotherapy while combating multidrug resistance (MDR) in cancer cells. MDR often limits the effectiveness of cancer treatments as cancer cells expel drugs before they can be effective. Rutherrin inhibits this drug expulsion, leading to higher drug retention and increased cancer cell kill rates. The research used various chemotherapeutic drugs and demonstrated significant improvements in drug retention and cancer cell mortality in vitro and in animal models. These findings suggest Rutherrin could significantly enhance current cancer treatments by overcoming MDR, reducing adverse effects, and improving patient outcomes.

Theralase Technologies has announced promising preclinical results for its lead compound, RuvidarTM, when combined with Bacillus Calmette-Guérin (BCG) to form RuBCG. The new compound significantly enhances the efficacy of BCG in killing bladder cancer cells by reversing the negative charge of BCG, allowing better adhesion to cancer cells. In experiments, RuBCG increased cancer cell kill rates and decreased immune checkpoint inhibitor PD-L1 levels. The results suggest RuBCG could offer a more effective treatment for Non-Muscle Invasive Bladder Cancer (NMIBC), potentially overcoming the limitations of BCG alone.

Theralase Technologies announced that its lead compound, Ruvidar, combined with transferrin to form Rutherrin, has shown preclinical effectiveness in destroying Non-Small Cell Lung Cancer (NSCLC). Experiments using a Lewis Lung Cancer model demonstrated that Rutherrin stays longer in tumor tissues than in normal lung tissues, leading to enhanced selectivity. All mice treated with x-ray activated Rutherrin survived, showing up to a 4-fold slower tumor progression compared to those treated with radiation alone. Theralase plans to start a Phase Ia clinical study for GBM and NSCLC in Q4 2024, with possible expansions into other cancers like pancreatic, prostate, kidney, and colorectal cancers, pending successful GLP toxicology results and capitalization.

Theralase Technologies announced that its lead compound, RuvidarTM, has proven effective in inactivating various viruses, including enveloped and non-enveloped ones. Research conducted at the University of Manitoba and the National Microbiology Laboratory demonstrated RuvidarTM's potency, showing effectiveness at concentrations 100 times lower than previously tested antiviral compounds. The findings, published in Heliyon, suggest that RuvidarTM could be a broad-spectrum viral vaccine candidate, particularly effective against viruses such as H1N1 influenza, coronavirus, Zika, and herpes. Theralase plans to focus on developing RuvidarTM for commercial use, including a topical therapeutic for herpes lesions. The company's shift in research focus towards developing an avian influenza vaccine has also gained consensus from the National Microbiology Laboratory.

Theralase Technologies, a clinical-stage pharmaceutical company, released its unaudited interim consolidated 1Q2024 financial statements. Key highlights include a 15% YoY revenue decline, with a gross margin of $62,114, down from $92,523 in 2023. Costs and expenses saw varied changes, with a notable 20% decrease in Drug Division R&D expenses to $725,017 and an 886% increase in Device Division R&D expenses to $31,363. Net loss reduced by 10% to $1,266,711.

Operationally, Theralase closed a $750,200 private placement and made significant progress in Study II, treating 68 patients, with a 63% complete response rate. Key updates on clinical data and Break Through Designation (BTD) submission to the FDA were also shared. The company aims for full patient enrollment in Study II by 2024 end, data lock by mid-2026, and FDA/Health Canada approval by late 2026.

Theralase Technologies Inc. announces the addition of two Clinical Research Associates to its team to support the Phase II registration bladder cancer clinical study. The CRAs will facilitate the launch of new clinical study sites, patient enrollment, data review, ethics board approval, training, and Break Through Designation approval from the FDA. The company aims to commercialize RuvidarTM to provide a safe and effective treatment for bladder cancer patients.

Theralase(R) Technologies Inc. announces the successful closure of a $CAN 750,000 Non-Brokered Private Placement offering, issuing 4,167,778 Units at $CAN 0.18 per Unit. The funds will be used for advancing clinical studies, research, working capital, and general corporate purposes. The securities are not registered under the U.S. Securities Act and have a hold period until August 25th, 2024.

Theralase Technologies Inc. receives a Canadian patent for a new cancer vaccine based on Photo Dynamic Compounds. The patent allows for the treatment of various cancers by inactivating cancer cells and programming the patient's immune system to destroy the cancer. Theralase's pipeline includes clinical studies for bladder, brain, and lung cancer, with plans to explore liquid cancers like leukemia and lymphoma. The company aims to secure financing for new clinical studies.

Theralase Technologies Inc. releases audited 2023 financial statements, hosting conference call to discuss results. Financial highlights show a 6% revenue decrease, gross margin decrease, decreased selling expenses, increased administrative expenses, and a 392% increase in stock-based compensation expense. Net loss decreased by 13%. Operational highlights include non-brokered private placements, Study II updates, Break Through Designation progress, and Study II preliminary clinical data showcasing positive results.